Benjamin Edwards Inc. Purchases 1,802 Shares of Eli Lilly and Company (NYSE:LLY)

Benjamin Edwards Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 13.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,265 shares of the company's stock after buying an additional 1,802 shares during the period. Benjamin Edwards Inc.'s holdings in Eli Lilly and Company were worth $11,802,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Highline Wealth Partners LLC increased its holdings in Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after buying an additional 20 shares during the last quarter. FPC Investment Advisory Inc. increased its holdings in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after acquiring an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $48,000. Compass Financial Services Inc bought a new position in Eli Lilly and Company during the fourth quarter worth $50,000. Finally, Fiduciary Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter worth $58,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.14% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Cantor Fitzgerald began coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target on the stock. Finally, Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research note on Friday, January 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $1,002.80.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $45.20 during trading on Tuesday, reaching $776.26. The company had a trading volume of 5,961,205 shares, compared to its average volume of 3,485,577. The firm's 50 day simple moving average is $820.91 and its two-hundred day simple moving average is $814.03. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market capitalization of $735.69 billion, a PE ratio of 66.29, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.58 earnings per share. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.